• EE170 Cost-Effectiveness of a Digital Diabetes Prevention Program (DDPP) in Prediabetic Patients

    Dec 1, 2022, 00:00

  • EE454 A Distributional Cost-Effectiveness Analysis of Screening Strategies for Ovarian Cancer

    Dec 1, 2022, 00:00

  • EPH59 Physicians’ Preferences for the Medical Management of Subarachnoid Hemorrhage Post Aneurysm Repair

    Dec 1, 2022, 00:00

  • PCR32 Self-Reported Prevalence and Impact of Clinical Signs, Symptoms, and Events in Adults With Osteogenesis Imperfecta (OI)

    Dec 1, 2022, 00:00

  • EE383 The Economic Burden of COVID-19 Prevention and Cases Management in Egypt from Governmental Perspective

    Dec 1, 2022, 00:00

  • HPR67 Identifying the Key Challenges in the Reimbursement of Next Generation Sequencing and Future Policy Changes in Europe Using a Web-Based Portal to Engage Payers

    Dec 1, 2022, 00:00

  • EE172 The Wisdom Self-Management Intervention: A Cost-Effectiveness Analysis to Support the Transformation of Type 2 Diabetes Care in England

    Dec 1, 2022, 00:00

  • EPH182 Inpatient Burden of Respiratory Syncytial Virus in Children ≤2 Years of Age in Germany: A Retrospective Analysis of Nationwide Hospitalization Data, 2019-2021

    Dec 1, 2022, 00:00

  • CO29 The Very Long-Term Durability of TEVAR for Traumatic Aortic Transection Determined by Real-World Evidence

    Dec 1, 2022, 00:00

  • EPH126 Sex- and Age-Adjusted Incidence and Prevalence Population-Based Estimation for Acute Myeloid Leukemia in Korea From 2011 to 2019

    Dec 1, 2022, 00:00

  • HPR32 The Payers’ and Clinicians' Approach to Burden of Disease and Unmet Health Need in a Rare Disease in Poland, Greece, and the Czech Republic - Similarities and Differences

    Dec 1, 2022, 00:00

  • MT31 A Novel Medical Technology for Rapid Molecular Diagnostics (Nicking Enzyme Amplification Reaction [NEAR]) - A Systematic Literature Review, Meta-Analysis

    Dec 1, 2022, 00:00

  • HPR106 The Challenges of Outcomes-Based Reimbursement for Advanced Therapy Medicinal Products in Europe

    Dec 1, 2022, 00:00

  • PCR83 Investigation of Functional Outcomes at Hospital Discharge in Hip Replacement Patients in Different Health Care Sectors

    Dec 1, 2022, 00:00

  • EE410 Examining the Cost-Effectiveness of Biomarker Testing in Oncology Studies: Should the Health Systems Invest in It?

    Dec 1, 2022, 00:00

  • MSR97 Systematic Literature Review of the Efficacy and Safety of Pharmacological Treatments and Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy

    Dec 1, 2022, 00:00

  • MSR29 Benchmarking Current Practices in Data Visualisation in HEOR, Identifying Gaps and Suggesting Improvements

    Dec 1, 2022, 00:00

  • RWD8 Patient Preferences in Chronic Immune-Mediated Inflammatory Diseases Potentially Treated With Biological Drugs: Real-World Data Analysis

    Dec 1, 2022, 00:00

  • MT35 The Economic and Capacity Impact of Time Saved in the Operating Theatre Performing Holmium Laser Enucleation of the Prostate with Moses™ Technology vs Standard Technology

    Dec 1, 2022, 00:00

  • EE343 Assessing Impact of Kidney Cancer-Related Premature Mortality and Productivity Loss in Greece and Portugal

    Dec 1, 2022, 00:00

  • RWD54 Healthcare Resource Use and Associated Costs of Congenital Thrombotic Thrombocytopenic Purpura in France

    Dec 1, 2022, 00:00

  • HTA102 Machine-Learning Technology Assisted Curated Reference Libraries as an Approach for Rapid Global Value Dossier Updates to Support Living Health Technology Assessment: A Case Study in Triple Refractory Multiple Myeloma (TRMM)

    Dec 1, 2022, 00:00

  • EE340 Impact of Quality of Evidence on Cost-Effectiveness Outcomes for New Products: Pilot Study for a Hypothetical New Therapy for HR+/HER2- Metastatic Breast Cancer (MBC)

    Dec 1, 2022, 00:00

  • PCR101 Understanding the Burden of Disease for Pediatric and Adult Patients With Classic Galactosemia: A Survey and Interview Study

    Dec 1, 2022, 00:00

  • Analytic Methods for the Effectiveness of Immunotherapies in Oncology

    Dec 1, 2022, 00:00

  • P19 How Is Real-World Evidence Really Being Used in Health Technology Assessments – A Canadian Case Study

    Dec 1, 2022, 00:00

  • EE210 Epidemiology, Patients’ Characteristics and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Analysis in Italy

    Dec 1, 2022, 00:00

  • HPR49 Are Countries Using ATC Classification and Defined Daily Dose for Pricing and Reimbursement Decisions of Pharmaceuticals?

    Dec 1, 2022, 00:00

  • HTA193 Criteria for Value Assessment of Medication Adherence-Enhancing Interventions: Preliminary Results of a Systematic Review

    Dec 1, 2022, 00:00

  • MSR54 A Comparison of MAIC and STC Methods to Support the Decision at Feasibility Assessment Stage

    Dec 1, 2022, 00:00

  • HTA172 External Control Arm Studies in the Context of Pricing and Reimbursement Assessments – Overview on Guidance and Evaluation in Europe

    Dec 1, 2022, 00:00

  • MSR61 Lessons Learned From Network Meta-Analysis of Survival Data With Fractional Polynomials

    Dec 1, 2022, 00:00

  • PCR132 Is Walking as Important as Communicating After Stroke? Preference Weighting of ICF's Core Elements

    Dec 1, 2022, 00:00

  • CO146 Potential Predictors Affecting Access to Breast Cancer Screening Among Women in the United States Using the Health Behavioral Model: A MEPS Panel Analysis

    Dec 1, 2022, 00:00

  • HPR157 Repurposed Drugs Launched Under the AMNOG in Germany: Effects on Benefit Assessment and Price Development

    Dec 1, 2022, 00:00

  • EE287 Indirect Costs of Multiple Myeloma in Portugal

    Dec 1, 2022, 00:00

  • P20 Health Technology Assessment Based on Real-World Data: Estimating Lifetime Survival and Costs With Empirical Examples from Taiwan

    Dec 1, 2022, 00:00

  • HPR159 Neovascular Age-Related Macular Degeneration (NAMD) in Italy: A Social Cost Analysis

    Dec 1, 2022, 00:00

  • EPH194 Risk Factors Affecting Caries Development Among Primary School Children

    Dec 1, 2022, 00:00

  • EE154 Reassessment of a Cost-Effectiveness Analysis of Etonogestrel Implant Compared to Other Contraceptive Methods Based on Real Life Data in France

    Dec 1, 2022, 00:00

  • EE510 A Global Analysis of the Value of Precision Medicine in Oncology – The Case of Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • EE121 Cost-Effectiveness of Family Based Treatment for Pediatric Obesity: A Literature Review

    Dec 1, 2022, 00:00

  • EPH47 Early Hospital Management of Ageing Disease: Retrospective Study From a National Claims Database

    Dec 1, 2022, 00:00

  • RWE Applications in Health Technology Assessment

    Dec 1, 2022, 00:00

  • EE619 The Economic Impact of Empagliflozin in Adult Patients With Chronic Heart Failure in Spain

    Dec 1, 2022, 00:00

  • EE385 Cost Effectiveness of Gender-Neutral Vaccination With Gardasil 9 Against HPV in Greece

    Dec 1, 2022, 00:00

  • HPR189 Estimating the Impact of Generic Drug Entry on Cost Effectiveness of New Drugs

    Dec 1, 2022, 00:00

  • HSD89 Early Detection of Breast Cancer in Indonesia: Barriers Identified in a Qualitative Study

    Dec 1, 2022, 00:00

  • EE52 Cost-Minimisation Analysis of Ravulizumab Compared With Eculizumab in Patients With Atypical Hemolytic Uremic Syndrome (AHUS) in the Netherlands

    Dec 1, 2022, 00:00

  • HPR1 Development of an Economic Evaluation Guideline in Lebanon

    Dec 1, 2022, 00:00

  • RWD39 Using Linked Databases to Explore Resource Use and Real-World Outcomes in a Rare Disease: Fabry Disease in England

    Dec 1, 2022, 00:00

  • CO99 Does Use of Digital Health Interventions in Diabetes Improve Patient Outcomes? Evidence From a Targeted Literature Review

    Dec 1, 2022, 00:00

  • EE191 A Budget Impact Analysis of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres Versus Atezolizumab-Bevacizumab as First-Line Therapy in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma in England

    Dec 1, 2022, 00:00

  • EE79 Cost-Effectiveness of Earlier Whole-Genome Sequencing in Rare Genetic Childhood Epilepsy

    Dec 1, 2022, 00:00

  • PCR78 Types of Headaches and Their Impact on Everyday Activities

    Dec 1, 2022, 00:00

  • EPH69 Health Inequity in Viral Infections in a Medicaid Population: Lessons From Influenza and COVID-19

    Dec 1, 2022, 00:00

  • EPH192 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics

    Dec 1, 2022, 00:00

  • HSD2 Reusable Soft Mist Inhalers Have an Improved Carbon Footprint Compared With Dry Powder Inhalers and Pressurised Metered-Dose Inhalers

    Dec 1, 2022, 00:00

  • PCR58 The Use of Argumentation Based Synthesis to Interrogate Evidence to Support Treatment Decisions Reflecting Individual Preferences

    Dec 1, 2022, 00:00

  • HPR127 Managing Uncertainty for the Orphans: A Belgian Perspective on Managed Entry Agreements for Orphan Drugs

    Dec 1, 2022, 00:00

  • HPR151 Has Project Orbis Facilitated Faster Access to Oncology Therapies in Great Britain Following 'Brexit'?

    Dec 1, 2022, 00:00

  • EPH52 Odds Ratio of Each Disease Before Incidence of Alzheimer's Disease - A Case Control Study Using Japanese Health Insurance Claims Data

    Dec 1, 2022, 00:00

  • HTA135 Accessibility and Inclusivity for People Participating in Health Preference Research: How Does the Mode of Administering an Interview Impact on Time Trade-Off Studies?

    Dec 1, 2022, 00:00

  • RWD117 Body Surface Area of Adult Cancer Patients: An Italian Multicenter Retrospective Study

    Dec 1, 2022, 00:00

  • EE671 Budgetary Impact and Health Outcomes of Implementing New Treatment Guidelines for Heart Failure in Norway

    Dec 1, 2022, 00:00

  • HTA232 Indirect Treatment Comparison Methods in NICE Immuno-Oncology Technology Appraisals: Implementation and Critique

    Dec 1, 2022, 00:00

  • HSD73 First- and Second-Line Treatment Patterns in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Chart Review Study in Three Countries

    Dec 1, 2022, 00:00

  • EPH191 The Epidemiology of Male Breast Cancer in Eight High-Income European Countries

    Dec 1, 2022, 00:00

  • EE189 Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification

    Dec 1, 2022, 00:00

  • EPH96 Risk Factors for Below-the-Knee Amputation in Japanese Patients With Critical Limb Ischemia Who Underwent Plain Old Balloon Angioplasty Therapy: A Claims Database Analysis

    Dec 1, 2022, 00:00

  • PCR153 A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METex14) Skipping

    Dec 1, 2022, 00:00

  • SA69 Differences in Evidence Requirements of HTA Authorities in UK, Italy, Netherlands, Poland, Portugal, and Sweden to Appraise New Products

    Dec 1, 2022, 00:00

  • EPH151 Clinical and Economic Benefits of Prompt Initiation of Single-Inhaler Triple Therapy in COPD Patients in England Following an Exacerbation

    Dec 1, 2022, 00:00

  • MT24 Oxidized Zirconium Can Positively Impact Outcomes in Revision Arthroplasty: A 90-Day Episode of Care Analysis in a Large US Metropolitan Statistical Area (MSA) Following Revision Knee (RKA) and Hip Arthroplasty (RHA)

    Dec 1, 2022, 00:00

  • PCR12 Health-Related Quality of Life in German Early Benefit Assessment of Cancer Drugs: How Evidence-Based Are the Instruments Used?

    Dec 1, 2022, 00:00

  • EE400 Comparing the Budget Impact of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres Versus Drug Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma in England

    Dec 1, 2022, 00:00

  • MSR26 The Use of Disease-Specific Health-Related Quality of Life (HRQOL)/ Patient Reported Outcomes (PROS) Scales in Rare Inflammatory Conditions (RICS)

    Dec 1, 2022, 00:00

  • CO68 Pooled Subgroup Analysis of Patient-Reported Outcomes at Week 52 Among Patients Achieving the Primary Endpoint of F-VASI75 at Week 24 in Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo

    Dec 1, 2022, 00:00

  • EE222 Evaluating the Budget Impact on the Health Care System in England and Wales of RefluxStop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD)

    Dec 1, 2022, 00:00

  • EE376 Cost-Effectiveness of Complete Guideline-Adherent Use of Coronary Angiography From the German Payer Perspective

    Dec 1, 2022, 00:00

  • EE94 Cost-Effectiveness Analysis of Vaccinating Against Herpes Zoster With Adjuvanted Recombinant Zoster Vaccine in Switzerland

    Dec 1, 2022, 00:00

  • HTA244 Inclusion of Carer Health-Related Quality of Life (HRQOL) in National Institute for Health and Care Excellence (NICE) Appraisals Published Since 2019

    Dec 1, 2022, 00:00

  • EE652 Cost Effectiveness Analysis of Pembrolizumab for the Treatment of Advanced or Metastatic Renal Cell Carcinoma

    Dec 1, 2022, 00:00

  • RWD126 Introducing the German MSDS-AOK PLUS Database: Linkage of Administrative Claims Data and a Patient Registry for Advanced RWE Capabilities in Multiple Sclerosis

    Dec 1, 2022, 00:00

  • EE521 Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Bone Conduction Implants (BCI): A Case Study of a Longitudinal Economic Analysis and a Markov Model-Based Simulation.

    Dec 1, 2022, 00:00

  • PCR264 Quality of Life and Disability Among Patients With Chronic Lower Back Pain

    Dec 1, 2022, 00:00

  • HTA186 Cost-Effectiveness Analysis of Tirbanibulin for the Treatment of Actinic Keratosis From a Scottish NHS Perspective

    Dec 1, 2022, 00:00

  • CO7 Evaluating Health Outcomes and Costs Related to In-Hospital Procedures for the Management of Mitral Valve Disease in Spain

    Dec 1, 2022, 00:00

  • EPH89 Epidemiology of Myxoid Round Cell Liposarcoma (MRCLS) in the European Union (EU27) – An Extrapolation From the United States (US) Surveillance, Epidemiology, and End Results (SEER) Research Database

    Dec 1, 2022, 00:00

  • HTA246 The SMC Ultra-Orphan Framework: 3-Year Report Card

    Dec 1, 2022, 00:00

  • SA21 A Multicountry Innovative Approach to Obtain Strategic Patient Journey Insights From External Stakeholders in a New Therapeutic Rare Disease Area

    Dec 1, 2022, 00:00

  • EPH61 Obesity and Glycemic Control Among People With Type 2 Diabetes in Europe: A Retrospective Cohort Analysis

    Dec 1, 2022, 00:00

  • HPR48 Reimbursement Policies Regarding Rare Diseases in Central and Eastern European Countries

    Dec 1, 2022, 00:00

  • EE518 An Early Cost-Effectiveness Analysis of Minimally Invasive Paddle-Type Spinal Cord Stimulation for the Treatment of Chronic Neuropathic Pain

    Dec 1, 2022, 00:00

  • HPR117 Meta-Indicators for Analysing Pharmaceutical Systems: The PPRI Indicators

    Dec 1, 2022, 00:00

  • EPH70 Transcription Errors in Ophthalmology: Current Burden and the Opportunity for Digital Technologies

    Dec 1, 2022, 00:00

  • PCR185 The Role of Patients’ Advocacy Groups in the Italian Health Care Ecosystem: Present and Future Perspectives

    Dec 1, 2022, 00:00

  • EE86 Evaluation of Long- Versus Short-Term Use of Patiromer on Healthcare Resource Utilization in the Patiromer Long-Term Use Evaluation (VALUE) Study

    Dec 1, 2022, 00:00

  • The Use of Generic Patient-Reported Outcome Measures in Emergency Department Surveys: Discriminant Validity Evidence for the Veterans RAND 12-Item Health Survey and the EQ-5D

    Dec 1, 2022, 00:00

  • MT15 Obvio-19 App Ease of Use of Cancer Patients for Reporting COVID-19 Symptomology (ONCOVID Study)

    Dec 1, 2022, 00:00

  • EPH54 Prevalence and Association of Sociodemographic Determinants With the Risk of Developing Type 2 Diabetes in Saudi Arabia: A Web-Based Cross-Sectional Survey Study

    Dec 1, 2022, 00:00

  • HTA90 Use of General Population Utilities in NICE Highly Specialised Technology Appraisals of Treatments With the Potential to Restore Normal Physiology

    Dec 1, 2022, 00:00

  • RWD154 Clinical Characteristics and Pathways of Care of Breast Cancer Patients Receiving Targeted Therapy in Hungary

    Dec 1, 2022, 00:00

  • HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe

    Dec 1, 2022, 00:00

  • EPH157 Physical Activity Level in Association with Mental Health Before and During the Restrictions of the First Three Waves of COVID-19 Pandemic Among Hungarian Adults

    Dec 1, 2022, 00:00

  • HPR69 Evaluation of Availability, Prices and Affordability of Breast Cancer Medicines in Kwara-Central Senatorial District, Nigeria

    Dec 1, 2022, 00:00

  • EPH173 Current Issues and Expected Challenges in Identification of Depression as a Cardinal Symptom Within Bipolar Disorder

    Dec 1, 2022, 00:00

  • HTA5 Methodological Frameworks for the HTA of Digital Health Technologies: A National and International Survey

    Dec 1, 2022, 00:00

  • RWD130 The Effect of the COVID-19 Pandemic in the Prevalence of Diabetes Mellitus Type 1 and 2 in Children and Young Adults in Gree Real World Data from Greece

    Dec 1, 2022, 00:00

  • PCR225 Quality of Life (QOL)-Related Mentions for Prevalent Diseases on Social Media Platforms in the US

    Dec 1, 2022, 00:00

  • EPH83 An One-Year Static Cross-Sectional Population Model to Assess the Infection Burden Across the Ageing Population: An Application to the Flemish County

    Dec 1, 2022, 00:00

  • PCR17 Capturing the Impact of Grief and Bereavement on Caregivers in NICE HST Appraisals

    Dec 1, 2022, 00:00

  • HSD61 Trends in Discontinuation of Lipid-Lowering and Antihypertensive Therapies: A Real-World Data Analysis in Italy

    Dec 1, 2022, 00:00

  • PCR269 People and Families Affected by Gsdia: An Analysis of Narrative Accounts Written by Caregivers and Individuals Living With GSDIa

    Dec 1, 2022, 00:00

  • MSR120 To Include an Error Once May Be Regarded as a Misfortune, to Include It Again Looks Like Carelessness

    Dec 1, 2022, 00:00

  • EE541 Cost-Effectiveness and Epidemiological Impact of a Novel 3-Antigen Vaccine for the Prevention of Hepatitis B in Adults in the United Kingdom

    Dec 1, 2022, 00:00

  • PCR233 The Case Studies of an Integrative Approach in Primary Healthcare of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Post-COVID-19 Patients

    Dec 1, 2022, 00:00

  • EE12 Cost of Stroke Management in Turkey

    Dec 1, 2022, 00:00

  • CO26 Types of the Most Frequent Provider of Ambulatory Diabetes Care and Its Impact on Continuity of Care, Medical Expenses Using National Health Insurance Database of Korea

    Dec 1, 2022, 00:00

  • HTA218 Best Practices for ECA Study Design to Support HTA Decision-Making in Europe

    Dec 1, 2022, 00:00

  • HPR161 A Long-Term Forecast of the Economic Impact of Gene Therapies in France

    Dec 1, 2022, 00:00

  • MSR112 Evaluating Colombia's Health Insurers Efficiency in Lung Cancer Management: A Data Envelopment Analysis

    Dec 1, 2022, 00:00

  • HTA113 Accounting for Caregiver Quality of Life in Cost-Effectiveness Analyses of Rare Genetic Disease of Obesity – A Case Study in the Swedish Context

    Dec 1, 2022, 00:00

  • HTA100 Association of NCPE Submission Outcomes in Ireland With Added Therapeutic Value (ASMR) Rating in France

    Dec 1, 2022, 00:00

  • PCR292 Health State Utility Values (HSUVs) and Health-Related Quality of Life (HRQoL) in People Living With HIV/AIDS (PLWH): A Systematic Literature Review (SLR)

    Dec 1, 2022, 00:00

  • MSR114 Current Scenario of ‘Scenario Analysis’ in Health Economic Modelling in Oncology: A Review of NICE Appraisals

    Dec 1, 2022, 00:00

  • CO2 Long-Term Survival After an Acute Stroke in Brazil From 2012-2021: A Population-Based Cohort Study From a Healthcare Plan

    Dec 1, 2022, 00:00

  • EE457 Forecasting Social Welfare GainsFfrom Biosimilar Entries in the Basal Insulin Market

    Dec 1, 2022, 00:00

  • EE317 An Unresolved Paradox: The Additional Challenge of Demonstrating Cost-Effectiveness for Innovative Treatments Addressing Diseases With High Unmet Need

    Dec 1, 2022, 00:00

  • HTA114 Review of Health Technology Assessment (HTA) and Recommendations for the Introduction of Higher-Valency Pneumococcal Conjugated Vaccine (PCV) in 4 European Countries, The United-Kingdom (UK), and The United-States (US)

    Dec 1, 2022, 00:00

  • EE141 Cost-Effectiveness of TP53 and IGHV Biomarker Testing Prior to First-Line Treatment With Novel Agents for Chronic Lymphocytic Leukemia

    Dec 1, 2022, 00:00

  • EPH29 The Cost of Managing Safety Events: Ozanimod Versus Tofacitinib – A UK Perspective

    Dec 1, 2022, 00:00

  • MSR79 Synthesis of Survival Outcomes in Economic Evaluation: Does the Network Meta-Analysis Model Matter?

    Dec 1, 2022, 00:00

  • PCR116 Quality of Life of and Economic Burden on Caregivers of Individuals With Sickle Cell Disease in the UK and Fran A Cross-Sectional Survey

    Dec 1, 2022, 00:00

  • CO9 Impact of Patient Blood Management (PBM) on the Reduction of Transfusion Requirements and Length of Hospital Stay in Patients Undergoing Major Planned Orthopedic in Germany

    Dec 1, 2022, 00:00

  • HSD68 Barriers and Facilitators of Shared Decision Making in Clinical Practi An Umbrella Review

    Dec 1, 2022, 00:00

  • HPR188 Characterizing the Relevance of IRP for Medical Devices: A Cross-Country Comparison

    Dec 1, 2022, 00:00

  • RWD62 PAP Smear Screening Trend and Disparity in the US, 2016 – 2020

    Dec 1, 2022, 00:00

  • CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting

    Dec 1, 2022, 00:00

  • HTA175 Health Technology Assessment Decisions in Sweden and Denmark: A Comparative Study in Understanding the Challenges of Approval for Single-Arm Trials

    Dec 1, 2022, 00:00

  • HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19

    Dec 1, 2022, 00:00

  • RWD111 Influenza Vaccine Sales During the COVID-19 Era

    Dec 1, 2022, 00:00

  • CO1 The Health Outcome Analysis of Sintilimab for the First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: According to the Eq-5D-5L

    Dec 1, 2022, 00:00

  • EE311 Polyethylene Glycol Hydrogel Versus Fibrin Glue Sealant for Posterior Fossa Surgery: A Budget-Impact Analysis in Five European Countries

    Dec 1, 2022, 00:00

  • EE577 Cost-Consequence Analysis of EPTFE Vascular Grafts With Heparin End Point Covalent Bond Compared to Standard EPTFE Vascular Grafts in Below-Knee Surgical Bypass for Critical Limb Ischaemia Pad Patients in Portugal

    Dec 1, 2022, 00:00

  • PCR212 Symptoms and Impacts Important to Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (adv/met NSCLC): Results of a Qualitative Research Study

    Dec 1, 2022, 00:00

  • EE62 The Societal Burden of Bardet-Biedl Syndrome in the United States

    Dec 1, 2022, 00:00

  • HPR207 Are the Incremental Added Benefit and Price Claimed in Agreement With the Clinical Evaluation and the Price Setting? A Retrospective Analysis in France (2016-2021)

    Dec 1, 2022, 00:00

  • RWD97 Cost of COPD Hospitalizations in the Brazilian Public Health

    Dec 1, 2022, 00:00

  • CO69 A Systematic Literature Review (SLR) of the Clinical Evidence for Treatment of Differentiated Thyroid Cancer (DTC) After Prior Systemic Therapy

    Dec 1, 2022, 00:00

  • HTA273 A Health Technology Assessment of Three Personalized Nutrition Interventions Using the Eunethta HTA Core Model

    Dec 1, 2022, 00:00

  • HSD115 Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec

    Dec 1, 2022, 00:00

  • EE402 Social and Economic Burden of Breast Cancer in Russia

    Dec 1, 2022, 00:00

  • HPR76 Implementing the Recovery and Resilience Fund Initiative to Reduce Pharmaceutical Expenditure Clawback in Gree The Impact on Pharmaceutical Spending and on National Economy

    Dec 1, 2022, 00:00

  • EE471 Cost Effectiveness of Newborn Screening (NBS) for Spinal Muscular Atrophy (SMA) in England

    Dec 1, 2022, 00:00

  • HPR149 Global Pricing, Reimbursement and Market Access Trends for Regenerative Medicines, ATMPs, Cell, Gene Therapies

    Dec 1, 2022, 00:00

  • PCR265 Preferences and Needs of Heart Failure Patients Regarding Their Treatment and Care

    Dec 1, 2022, 00:00

  • EE103 Evaluating the Need for Automated Technology Solutions in Annual Therapy Cost Calculations in German Early Benefit Assessment Dossiers

    Dec 1, 2022, 00:00

  • HTA149 Early Access Reform in Fran Descriptive Analysis of First EAP Decisions

    Dec 1, 2022, 00:00

  • RWD112 Can ML-Extracted Variables Reproduce Real World Comparative Effectiveness Results From Expert-Abstracted Data? A Case Study in Metastatic Non-Small Cell Lung Cancer Treatment

    Dec 1, 2022, 00:00

  • EE420 Valuation of Lost Productivity for Individuals Diagnosed With Osteogenesis Imperfecta: Follow-up Findings From the Rudy Cohort Study in the UK

    Dec 1, 2022, 00:00

  • HTA101 Diagnostic Testing (DTx) Costs: A Hidden Barrier to Accessing Histology-Independent Technologies (HITs)

    Dec 1, 2022, 00:00

  • PCR112 Expected Pricing and Access Hurdles in the US for Novel Rheumatoid Arthritis Therapies

    Dec 1, 2022, 00:00

  • HPR172 How Thalassemia Is Prevented in China: A Policy Review and International Comparison

    Dec 1, 2022, 00:00

  • MSR7 Multiplicative With Linear Transformation (MLT): An Improvement on the Multiplicative Method for Age and Sex Adjustment of Utilities?

    Dec 1, 2022, 00:00

  • HSD98 Effects of Process Changes on Emergency Department Crowding in a Changing World: An Interrupted Time-Series Analysis

    Dec 1, 2022, 00:00

  • EE486 Budget Impact Analysis of Cenobamate as Novel Adjunctive Treatment for FOS in Epilepsy Patients Inadequately Controlled With at Least Three Anti-Seizure Medications for the Belgian Healthcare Payer

    Dec 1, 2022, 00:00

  • PCR154 Modelling Time-to-Death Utilities as a Continuous Function, Using a Rich Dataset of Patients With Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • HTA54 Incorporating Value of Health System Impact in Economic Evaluations of Therapies of Chronic Diseases

    Dec 1, 2022, 00:00

  • EE570 Estimation of Direct Medical Costs Associated With Genetic Consultations Among Moroccan Children With Rare Diseases: A Single-Center Retrospective Cost Analysis

    Dec 1, 2022, 00:00

  • EPH169 Global Epidemiology, Humanistic Burden, and Economic Burden of Astigmatism: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • P47 Understanding Evidence Requirements for Diagnostic Devices for Reimbursement and Market Access: Insights and Lessons From Review of NICE Diagnostics Assessment Reports (2011-2022)

    Dec 1, 2022, 00:00

  • MSR15 Using Advanced Parametric Survival Models for HTA Submissions in the Face of Short-Term Patient Follow-Up

    Dec 1, 2022, 00:00

  • EE433 Cost-Effectiveness Analysis of a New Second-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma in Taiwan: Genetic Test-Based Targeted Therapy of Pemigatinib Versus Chemotherapy of 5-FU

    Dec 1, 2022, 00:00

  • PCR65 Development of a Patient-Reported Outcome Measure in Wilson Disease

    Dec 1, 2022, 00:00

  • HSD108 Physician Perceptions on the Treatment and Health-Related Quality of Life Burden of Endogenous Cushing's Syndrome

    Dec 1, 2022, 00:00

  • Frameworks and Methods for the Design of Stated Preference

    Dec 1, 2022, 00:00

  • EPH187 Effects of Non-Pharmaceutical Interventions (NPIS) Aimed at Limiting the Spread of SARS-COV-2

    Dec 1, 2022, 00:00

  • EE104 Appraisal of the Multi-Criteria Decision Analysis Method to Improve Value Assessment of New Therapies

    Dec 1, 2022, 00:00

  • RWD37 Healthcare Resource Use and Associated Costs of Dengue Fever Requiring Hospitalization: A French National Real-World Study

    Dec 1, 2022, 00:00

  • P18 Cancer Drugs Fund Entry and Exit: A Comparison of Key Issues for Decision-Making in NICE Technology Appraisals

    Dec 1, 2022, 00:00

  • CO45 Real-World Clinical Outcomes of Secukinumab in Thai Patients With Psoriasis: Subgroup Analyses By Adherence Rate and Completeness of Loading Dose

    Dec 1, 2022, 00:00

  • HPR27 Is It Possible to Anticipate the Risk of Major Reservation Issued by the CEESP? A Retrospective Analysis of Published Opinions

    Dec 1, 2022, 00:00

  • MT32 Rise of the Machines – Analysis of Robotic-Assisted Surgery From 2005 to 2020 Based on German Hospital Data

    Dec 1, 2022, 00:00

  • CO167 The Incremental Benefit Provided by Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL) When Compared to Real-World Clinical Practice (RWCP)

    Dec 1, 2022, 00:00

  • EE327 Cost-Effectiveness Analysis of Cemiplimab for Patients With Advanced Non-Small Cell Lung Carcinoma in Spain

    Dec 1, 2022, 00:00

  • EE136 Cost of Illness in Patient With Synovial Sarcoma in México (2010-2021)

    Dec 1, 2022, 00:00

  • HTA53 Will NICE’S New Severity Weighting Criteria Be Capable of Identifying Severe Conditions?

    Dec 1, 2022, 00:00

  • HPR68 Retrospective Analysis of the Negotiation in AIFA for New Therapeutic Indications

    Dec 1, 2022, 00:00

  • HPR59 The Pharmaceutical Reimbursement and Access Pathways in the 27 EU Member States: Who Is Ready for Joint EU HTA?

    Dec 1, 2022, 00:00

  • EE233 Cost-Effectiveness of Ravulizumab Compared with Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in the Netherlands

    Dec 1, 2022, 00:00

  • EPH180 Acute Coronary Heart Syndrom (ACS): Hospitalizations in Germany Before and During COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • CO48 Systematic Literature Review and Meta-Analysis of Endoscopic Improvement for Treatment of Moderate-Severe Ulcerative Colitis

    Dec 1, 2022, 00:00

  • EE599 Cost-Effectiveness Analysis of Trastuzumab Emtansine for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in Greece

    Dec 1, 2022, 00:00

  • SA12 A Mixed-Methods Review of the Systematic Reviewer's Inter-Reviewer Reliability Using the Kappa Statistic

    Dec 1, 2022, 00:00

  • EE220 Healthcare Costs of Osteoporotic Fractures in Nigeria

    Dec 1, 2022, 00:00

  • EE463 Cost-Effectiveness of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Switzerland

    Dec 1, 2022, 00:00

  • EE503 Cost Implications of Hospice Care for Cancer Patients in Illinois Hospitals

    Dec 1, 2022, 00:00

  • HSD101 Policy Analysis of Eight Failed Telemedicine Experiments in the Paris Region

    Dec 1, 2022, 00:00

  • HPR86 Sustainability of Healthcare Systems in the Wake of COVID-19: The UK VPAS Case Study

    Dec 1, 2022, 00:00

  • PCR29 A Systematic Literature Review of Utility Estimates for Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

    Dec 1, 2022, 00:00

  • EPH92 Dysphagia Prevalence in Brazil, UK, China, and Indonesia and Dysphagic Patient Preferences

    Dec 1, 2022, 00:00

  • P7 A Pragmatic Framework to Tackle the Challenge of Developing Concise Attribute Lists for Stated Patient Preference Surveys

    Dec 1, 2022, 00:00

  • HTA233 Analysis: First Year of the New Early Access Authorization in France

    Dec 1, 2022, 00:00

  • RWD167 The Impact of Administration Modality on Quality of Life for Respiratory Diseases in Japan Based on Patient-Reported Outcomes

    Dec 1, 2022, 00:00

  • EE364 Reduced Healthcare Resource Use in Patients With Chronic Insomnia After Treatment With a Digital Therapeutic With 2-Year Follow-Up

    Dec 1, 2022, 00:00

  • EPH139 Deprivation and Access to Care Among Patients With Melanoma in the UK

    Dec 1, 2022, 00:00

  • EPH44 Prevalence and Risk Profile of Emerging Multidrug Resistance in Klebsiella Pneumoniae/ Enterobacteriaceae: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • CO119 Systematic Review and Meta-Analysis of Mucosal Healing Outcomes With Biologics in Treatment of Ulcerative Colitis and Crohn's Disease

    Dec 1, 2022, 00:00

  • PCR74 Development of Conceptual Frameworks and Patient-Reported Outcome Measures in Glycogen Storage Disease Type Ia (GSDIa)

    Dec 1, 2022, 00:00

  • EE325 Cost-Effectiveness of Lung Cancer Screening With Low Dose Computed Tomography in Hungary

    Dec 1, 2022, 00:00

  • CO95 The Relationship Between Asthma Control Questionnaire Scores and Exacerbation Risk, Resource Utilization, and Utility Values: An Analysis From the Captain Trial

    Dec 1, 2022, 00:00

  • HTA34 Quo Vadis Benefit Assessment for Orphan Drugs in Germany: The End of the Exception?

    Dec 1, 2022, 00:00

  • SA75 Exploring the Relationship Between Comorbidities and Alzheimer's Disease Progression Assessed Using the Clinical Dementia Rating Scale: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • CO157 The Clinical and Economic Impact of Nationwide Insurance Coverage for Next-Generation Sequencing in Advanced Ovarian Cancer: A Retrospective Observational Study Using the Nationwide Database in South Korea

    Dec 1, 2022, 00:00

  • PCR103 Patients and Neurologists’ Preferences for Remote Patient Monitoring and Artificial Intelligence to Improve Parkinson's Disease Management

    Dec 1, 2022, 00:00

  • RWD55 Immunosuppressive (IS) Treatment Patterns Following Kidney Transplant in Fran A Real-World Retrospective Cohort Using the French National Health Data System (SNDS) Claim Databases Oister Study

    Dec 1, 2022, 00:00

  • MT28 Effects of Mobile Health-Based Personalized Disease Management Program Intervened by Health Professionals Through a Mobile App and Telephone Interviews in Reducing Medical Costs

    Dec 1, 2022, 00:00

  • HTA70 Four Is the New Seven: The Application of New Routing Criteria for NICE’S Highly Specialised Technology Programme

    Dec 1, 2022, 00:00

  • EE71 Cost-Effectiveness of Screening for Hydroxychloroquine Retinopathy

    Dec 1, 2022, 00:00

  • HPR134 Health Policy Analysis of Written Question Motions Submitted to the Presidency and Ministries by the Deputies Between 2018–2022 in Turkiye

    Dec 1, 2022, 00:00

  • Copyright/Subscription

    Dec 1, 2022, 00:00

  • CO156 The Comparative Postoperative Outcomes between Robotic-Assisted Lobectomy and Video-Assisted Thoracoscopic Surgery for Treating Lung Cancer in Japan

    Dec 1, 2022, 00:00

  • EE409 Cost Effectiveness of Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

    Dec 1, 2022, 00:00

  • EE338 The Potential Benefit of Respiratory Syncytial Virus (RSV) Vaccination in Older Adults: A Comparison of the United States (US) and United Kingdom (UK)

    Dec 1, 2022, 00:00

  • SA62 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in Asthma in England: A Population-Based Study

    Dec 1, 2022, 00:00

  • EE382 Cost-Utility Analysis of Avacopan for the Treatment of Anca-Associated Vasculitis (AAV) Patients in the UK

    Dec 1, 2022, 00:00

  • RWD78 First Real-World Evidence Study of Patients With Hemophilia in Algeria

    Dec 1, 2022, 00:00

  • PCR5 Healthcare Resource Use, Productivity and Quality of Life in Patients With Migraine: Results from Overcome (EU) Study

    Dec 1, 2022, 00:00

  • Incorporating Informal Care Considerations in HTA

    Dec 1, 2022, 00:00

  • EE159 Economic Burden of Malignant Pleural Mesothelioma in Europe: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • HPR28 Last Resort for Reimbursement of New Drugs in Germany: When the Arbitration Office Must Decide

    Dec 1, 2022, 00:00

  • PCR236 Estimating Health Utilities for Health States of Patients With Stroke Using the SF-6D

    Dec 1, 2022, 00:00

  • CO15 A Matching-Adjusted Indirect Comparison of Efgartigimod Versus Ravulizumab for Generalized Myasthenia Gravis

    Dec 1, 2022, 00:00

  • HPR199 Public Procurement of Medicines: A Taxonomy of Procurement Systems in Europe

    Dec 1, 2022, 00:00

  • HTA96 Health Economic Modelling for HTA Assessment: A Comparison of Economic Protocols Submitted to Three HTA Bodies (HAS, NICE, CADTH)

    Dec 1, 2022, 00:00

  • EE661 Impact on Health-Economic Evaluations of the Extrapolation Method Regarding the Efficacy of Immunotherapies: Case Study in Renal Cell Carcinoma

    Dec 1, 2022, 00:00

  • PCR4 Disease-Specific Quality-of-Life Measures Mapped to the EQ-5D in a Chronic Disorder With Recurrent Attacks: Analysis of the Deliver Trial in Patients With Migraine

    Dec 1, 2022, 00:00

  • EE647 Real-Word Effectiveness and Cost Consequence of Antipsychotic Treatment Choices in the Treatment of Schizophrenia in Italy: A Bayesian Hierarchical Inference Model

    Dec 1, 2022, 00:00

  • EE455 Assessing the Consequences of Suboptimal Infant Vaccination Rates on Pertussis Costs in Brazil: A Prospective Modeling Analysis

    Dec 1, 2022, 00:00

  • EE291 Economic Evaluation of Metastatic Breast Cancer Following Trastuzumab-Based Treatment of HER2+ Early Breast Cancer in Hong Kong

    Dec 1, 2022, 00:00

  • HPR98 Availability and Reimbursement of Multiple Myeloma Drug Regimens in Spain

    Dec 1, 2022, 00:00

  • EE492 Cost-Effectiveness of Dabigatran for Thromboembolic Events Prevention in Atrial Fibrillation Patients

    Dec 1, 2022, 00:00

  • HPR205 Future-Proofing European Regulatory and Market Access Practices Based on Learnings From the COVID-19 Pandemic – Stakeholder Perspectives

    Dec 1, 2022, 00:00

  • HPR208 Analysis of Substitution Procurement Agreements and Financial Impact in a University Hospital Structure

    Dec 1, 2022, 00:00

  • EE540 Cost-Effectiveness of Vaccines Targeting Infectious Diseases - Has COVID-19 Changed the Landscape?

    Dec 1, 2022, 00:00

  • HPR164 Exploring Timelines for New Medicines Reimbursed in Ireland in 2021

    Dec 1, 2022, 00:00

  • CO60 Mortality Impact Following the EU Approval of Numerous Novel Non-Small Cell Lung Cancer (NSCLC) Therapies Between 2010-2020

    Dec 1, 2022, 00:00

  • PCR240 A Cross-Sectional Study of Disease Severity and Health Related Quality of Life in Epidermolysis Bullosa

    Dec 1, 2022, 00:00

  • CO114 Health Outcomes and Costs Related to the In-Hospital Procedures for the Management of Tricuspid Valve Disease in Spain

    Dec 1, 2022, 00:00

  • HTA183 AMNOG Benefit Assessment in Germany: Outcomes From 2011 to 2022

    Dec 1, 2022, 00:00

  • HPR34 Emerging Role of Patient Reported Outcomes in Drug Approval in Europe

    Dec 1, 2022, 00:00

  • HTA201 Access Challenges of Advanced Therapy Medicinal Products in Europe

    Dec 1, 2022, 00:00

  • HPR158 Progression Free Survival and Duration of Treatment as a Proxy of Disease Severity: Use of These Variables to Determine Price Benchmarks

    Dec 1, 2022, 00:00

  • HPR150 PR Policies and Macro-Trends Pertinent to CGTs: Where Are the Main Barriers and Who Leads the Efforts to a Greater Access?

    Dec 1, 2022, 00:00

  • PCR230 Understanding the Indirect Burden of Patients and Caregivers Impacted by Refractory/Relapsing Multiple Myeloma

    Dec 1, 2022, 00:00

  • HPR154 Appropriate Use of Anti-PD(L)1 in Paris Public Hospitals (AP-HP): Are the Prescriptions in Compliance with Reimbursed Indications?

    Dec 1, 2022, 00:00

  • EE213 Cost-Effectiveness Analysis of Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer

    Dec 1, 2022, 00:00

  • EE550 The Potential Cost and Cost-Effectiveness Impact of Using Machine Learning Sepsis Prediction Algorithm for Early Detection of Sepsis in Intensive Care Units in Sweden and the United Kingdom

    Dec 1, 2022, 00:00

  • SA19 A Systematic Literature Review of the Economic Burden of Surfactant Use in the Treatment of Neonates with Respiratory Distress Syndrome

    Dec 1, 2022, 00:00

  • HPR43 Differences in Inequalities of Uterine Cancer Treatment Before and After COVID-19 in England

    Dec 1, 2022, 00:00

  • HTA153 HTA Requirements in Central Eastern European Countries

    Dec 1, 2022, 00:00

  • EE328 A Flexible Program Compared to Algorithm-Guided Treatment Program for Depression: A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • PCR204 Qualitative Debriefing of the Cystic Fibrosis-Impact Questionnaire (CF-IQ) Among Adolescents With Cystic Fibrosis (CF)

    Dec 1, 2022, 00:00

  • EE251 A Budget Impact Analysis of the Introduction of Generics Ambrisentan and Tadalafil for the Treatment of Pulmonary Arterial Hypertension in Greece

    Dec 1, 2022, 00:00

  • PCR280 Development of a Patient-Reported Outcome Measure to Evaluate Self-Perception and Psychosocial Impact in Adolescents and Young Adults With Acne

    Dec 1, 2022, 00:00

  • EE112 Cost-Effectiveness of Digital Breast Tomosynthesis in Mammography Screening in Women With High Breast Density From a Czech Perspective

    Dec 1, 2022, 00:00

  • PCR25 Content Validity Assessment of a Newly-Developed Patient-Reported Outcome Measure for Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), and Sjogren's Syndrome Dry Eye Disease (SS-DED)

    Dec 1, 2022, 00:00

  • EPH45 Socio-Demographic Determinants of Childhood Vaccination in Indonesia: A Cross-Sectional Study

    Dec 1, 2022, 00:00

  • PCR115 Measurement of Therapeutic Adherence in Orphan Diseases: A Scoping Review

    Dec 1, 2022, 00:00

  • PCR278 Systematic Review on Health-Related Quality of Life and Utilities in Immunoglobulin A Nephropathy (IgAN)

    Dec 1, 2022, 00:00

  • HPR97 National Reimbursement Drug List Negotiation in China: Analysis of the Key Trends and Factors Influencing the Value Appraisal and Price Determination

    Dec 1, 2022, 00:00

  • HTA170 Including Decision-Analytic Benefit-Harm Evaluation in HTA - Different Age Ranges and Screening Intervals in Breast Cancer Screening in Germany

    Dec 1, 2022, 00:00

  • EPH30 Disability-Adjusted Life Years Lost Due to Migraine: A Nationwide Burden-of-Illness Study From the National Health Survey in Spain

    Dec 1, 2022, 00:00

  • HPR160 Analysis of the Time Spent by AIFA Committees for the Assessment of New Drugs: Impact of the Application of Managed Entry Agreements

    Dec 1, 2022, 00:00

  • RWD5 Using Linked Databases to Explore Resource Use and Real-World Outcomes in a Rare Disease: Pompe Disease in England

    Dec 1, 2022, 00:00

  • EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy

    Dec 1, 2022, 00:00

  • EPH15 Epidemiology of Patients Revascularized for Peripheral Artery Disease in France (2016-19): A Retrospective Observational Cohort Study Using the French Hospital Discharge Database (PMSI)

    Dec 1, 2022, 00:00

  • MSR5 Temporal Uncertainty and Decision-Making in Cost-Effectiveness Models

    Dec 1, 2022, 00:00

  • HTA47 Definition of a System of Factors to Improve the Quality of Decision-Making Process in Health Technology Assessment

    Dec 1, 2022, 00:00

  • PCR9 Development and Evaluation of Gaucher Disease-Specific Patient Reported Outcome Measurement in Japan

    Dec 1, 2022, 00:00

  • CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

    Dec 1, 2022, 00:00

  • EE289 A Study of Post Operation Hypotension Burden Model in Korea Using Hira National Inpatient Sample (HIRA-NIS) Data

    Dec 1, 2022, 00:00

  • HTA258 Health Technology Assessments of Single-Arm Clinical Trials in Germany and France

    Dec 1, 2022, 00:00

  • EE576 Potential Budget Impact of Negative Pressure Wound Therapy (NPWT) Versus Conventional Wound Treatment in Diabetic Foot Ulcers (DFU), Surgical and Trauma for Selected Countries in Latin America

    Dec 1, 2022, 00:00

  • HTA43 Multi-Country HTA Initiatives Versus National HTA Processes: The Optimal Reimbursement Strategy

    Dec 1, 2022, 00:00

  • MSR13 Methods for Handling EQ-5D Missing Values in Cost-Effectiveness Analyses (CEA) and Patient-Reported Outcome (PRO) Studies: A Targeted Literature Review

    Dec 1, 2022, 00:00

  • EE393 Cost Effectiveness Analysis of DTG/3TC Versus EVG/c/TAF/FTC and BIC/TAF/FTC for HIV-1 Infection Management in Treatment-Naïve Patients in China

    Dec 1, 2022, 00:00

  • EPH136 Landscape of Dyslipidemia in China

    Dec 1, 2022, 00:00

  • EPH196 Evaluation of Parents’ Attitude Toward Vaccines

    Dec 1, 2022, 00:00

  • HTA227 A Cross-Stakeholder Approach to Support the Acceptance of Non-Os Endpoints in Reimbursement Decision Making

    Dec 1, 2022, 00:00

  • SA81 Feasibility and Challenges of Virtual Time Trade-Off Interviews: The Case of the EQ-5D-3L Valuation Study in Jordan

    Dec 1, 2022, 00:00

  • MSR100 Applicability of Artificial Intelligence in Targeted Literature Review

    Dec 1, 2022, 00:00

  • CO126 Axicabtagene Ciloleucel for the Treatment of B-Cell Lymphoma- Gaps, Opportunities and Future Perspectives

    Dec 1, 2022, 00:00

  • EE185 Cost-Effectiveness of Transcatheter Aortic Valve Implantation in Low Surgical Risk Patients With Severe Symptomatic Aortic Stenosis in Germany

    Dec 1, 2022, 00:00

  • EE485 Budget Impact Model (BIM) of the Newly Proposed Value-Based Positive Airway Pressure (PAP) Therapy Based on Telemonitoring in Patients With Obstructive Sleep Apnea (OSA) in Spain.

    Dec 1, 2022, 00:00

  • HTA229 Use of Single-Arm Studies for Health Technology Assessment in Portugal

    Dec 1, 2022, 00:00

  • HTA121 Opportunities and Challenges of Cross-Country Collaborations in Market Access of Medicines: Stakeholder Perspectives on the BeNeLuxA Initiative

    Dec 1, 2022, 00:00

  • HSD4 Is the National Training Programme for Laparoscopic Colorectal Surgery (LAPCO) Value for Money?

    Dec 1, 2022, 00:00

  • EPH168 Assessment of the Prevalence of Emotional Burnout Among Medical Workers in the Republic of Kazakhstan

    Dec 1, 2022, 00:00

  • SA71 Validation Study of Algorithms to Identify Cancer Metastasis/Recurrence in Patients With High-Risk HR+/HER2- Early Breast Cancer (EBC) Using Japan Nationwide Hospital-Based Databases Owned By National Hospital Organization

    Dec 1, 2022, 00:00

  • HTA190 Discrete Event Simulation Model for Real-World Restricted Treatment Policies in End-Stage Heart Failure

    Dec 1, 2022, 00:00

  • EE614 Use of Value of Information in the Context of the Cancer Drug Fund in the UK

    Dec 1, 2022, 00:00

  • P44 Review of Methods Used to Estimate Treatment Effects Against Relevant Comparators Using Evidence From Single-Arm Studies in NICE Single Technology Appraisals

    Dec 1, 2022, 00:00

  • CO40 Vision-Related Quality of Life in Patients With Diabetic Macular Edema Treated With Brolucizumab 6 Mg vs Aflibercept 2 Mg in the Kestrel and Kite Studies

    Dec 1, 2022, 00:00

  • EE261 Cost and Resource Studies in Endometriosis: An Evidence Map

    Dec 1, 2022, 00:00

  • EE264 Predictions on the Health and Economic Effects for the Chilean Population With Type 2 Diabetes Mellitus Recently Diagnosed

    Dec 1, 2022, 00:00

  • EE31 Costs of Gist and Non-GIST STSs in Turkiye: A Delphi Panel Study

    Dec 1, 2022, 00:00

  • EE643 A Targeted Review of Cost-Effectiveness of Immunotherapies Used in Treatment of Metastatic Non-Small-Cell Lung Cancer Patients in EU-5, Sweden, and Switzerland

    Dec 1, 2022, 00:00

  • P64 Health-Related Quality of Life in HER2-Positive Early Breast Cancer Woman Using Trastuzumab: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • HPR155 The Use of Patient-Reported Outcomes for New Drugs Approval in Europe: A Review of European Public Assessment Reports From 2017 to 2021

    Dec 1, 2022, 00:00

  • HSD36 Generic Penetration in the Market for Antidiabetics, Lipid Modifying Agents and Psychoeleptics/Psychoanaleptics: A Comparative Analysis of Data From 18 European Markets

    Dec 1, 2022, 00:00

  • HPR10 Building Bridges Between Regulation, Health Technology Assessment and Clinical Guideline Development

    Dec 1, 2022, 00:00

  • PCR145 Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy (SMA) in Italy

    Dec 1, 2022, 00:00

  • EE171 Hospital Costs of Muscle-Invasive Urothelial Carcinoma (MIUC) Patients Undergoing Radical Surgery: A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)

    Dec 1, 2022, 00:00

  • HPR129 Reimbursement Status of European Medicines Agency Authorised Drugs in Spain

    Dec 1, 2022, 00:00

  • HPR15 Out-of-Pocket Pharmaceutical Payments and Their Poverty Impact on Patients in Greece

    Dec 1, 2022, 00:00

  • EE415 Cost Utility Analysis of Ocrelizumab Versus Fingolimod in Relapsing Remitting Multiple Sclerosis Patients in Egypt from Payor Perspective

    Dec 1, 2022, 00:00

  • EPH109 Impact of COVID-19 Pandemic on HPV Vaccine Initiation Rates in Adolescent Girls: Projected Time to Reverse Dose Deficits in France

    Dec 1, 2022, 00:00

  • PCR166 Online Elicitation of Personal Utility Functions (OPUF) – An Open, Modular Health Valuation Platform

    Dec 1, 2022, 00:00

  • HTA199 The Reality of Living Systematic Literature Reviews to Support Timely Healthcare Decisions: A Case Study in Relapsed/Refractory Multiple Myeloma

    Dec 1, 2022, 00:00

  • RWD138 Age-Distribution in ICD-10 Codes Used to Document Hospitalised RSV Burden in Infants in England

    Dec 1, 2022, 00:00

  • EE379 Potential Healthcare Resource Use and Associated Costs of Every 2-Months Injectable Cabotegravir+Rilpivirine Long-Acting Implementation in the Spanish NHS vs Daily Oral HIV Treatments

    Dec 1, 2022, 00:00

  • PCR117 Achieving Stringent Clinical Disease Control Criteria Is Associated With Improved Quality of Life Measures in Patients With Active Psoriatic Arthritis: Results From Two Phase 3 Randomised, Placebo-Controlled Studies

    Dec 1, 2022, 00:00

  • PCR41 Is Enhancing Health-Related Quality of Life Correlated to Direct-Acting Antivirals Adherence in Chronic Hepatitis C Virus Patients? A Romanian Prospective Cohort Study

    Dec 1, 2022, 00:00

  • SA53 Misdiagnosis and Disease-Exacerbating Medication Use in Patients With Neuromyelitis Optica Spectrum Disorder in the United States: A Retrospective Claims Analysis

    Dec 1, 2022, 00:00

  • HTA130 Value Contribution of Olipudase Alfa Therapy for the Treatment of Non-Central Nervous System Manifestations of Acid Sphingomyelinase Deficiency (ASMD) by Multi-Criteria Decision Analysis (MCDA)

    Dec 1, 2022, 00:00

  • PCR208 Developing a Conceptual Framework for Socioeconomic Impact Research in European Cancer Patients - A 'Best-Fit' Framework Synthesis

    Dec 1, 2022, 00:00

  • RWD99 The Financial Burden of DM on the Public Health System of Gree Using Big Data From Greece

    Dec 1, 2022, 00:00

  • HTA269 What Are the Emerging State-of-the-Art HTA Methods That Are Relevant to Harmonization of HTA Across Jurisdictions?

    Dec 1, 2022, 00:00

  • PCR214 The Value of Technology to Reduce Barriers to Clinical Trial Diversity and Facilitate the Development of Patient-Centric Medicine

    Dec 1, 2022, 00:00

  • HTA238 Uncovering the Hidden Rare Disease Gap Within NICE Appraisals

    Dec 1, 2022, 00:00

  • HTA31 Understanding Pricing and Reimbursement Conditions to Facilitate PR Negotiations in Spain: A 5-Year Review (2017-2022)

    Dec 1, 2022, 00:00

  • MSR84 Training Models for Machine-Enabled Systematic Literature Reviews: Do Large Datasets Always Give Better Results?

    Dec 1, 2022, 00:00

  • CO14 Patient-Reported Outcomes (PROS) With Ramucirumab Versus Placebo in Chinese Patients With Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein From the Randomized Phase 3 Reach-2 Study

    Dec 1, 2022, 00:00

  • CO5 The Challenges of Generating Patient-Relevant Outcomes and Other Evidence Sufficient to Satisfy European HTA Bodies in Acute Conditions Managed in the ICU

    Dec 1, 2022, 00:00

  • EE130 Cost-Utility of Cabonivo vs Sunitinib, Pazopanib and Ipinivo for First Line Advanced Renal-Cell Carcinoma in the Private Healthcare System in Brazil

    Dec 1, 2022, 00:00

  • EPH105 Changes in the Prevalence of Gestational Diabetes Mellitus and Associated Syndromes of Infants — The Case of Hungary

    Dec 1, 2022, 00:00

  • CO123 An Indirect Comparison of Efgartigimod Versus Rituximab for Generalized Myasthenia Gravis

    Dec 1, 2022, 00:00

  • HTA247 Real-World Evidence in Multiple Sclerosis (MS): HTA Decision-Making Influencer or Not?

    Dec 1, 2022, 00:00

  • EE243 Cost-Effectiveness Model Conceptualisation in Fibrodysplasia Ossificans Progressiva

    Dec 1, 2022, 00:00

  • HTA207 Managed Entry Agreements in the Context of Health Technology Assessment Recommendations in Ukraine: Analysis on the Stage of Development

    Dec 1, 2022, 00:00

  • EE597 Conducting Budget Impact Analysis (BIA) for Multiple HTA of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—There Is More Than Meets the Eye

    Dec 1, 2022, 00:00

  • EPH10 Social Determinants of Health in Swedish Administrative Data – Who, What, and How Often?

    Dec 1, 2022, 00:00

  • EE627 Inclusion of Environmental Sustainability in the Economic Analysis of Healthcare Interventions: A Review of Policy Approaches

    Dec 1, 2022, 00:00

  • EE615 Economic Burden and Quality of Life in Prurigo Nodularis: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • HPR5 Reimbursement of Pharmaceuticals in Turkey: Comparison With Approvals of the FDA Between 2010-2021

    Dec 1, 2022, 00:00

  • CO35 Project Ideate: Modelling Payments and Volatility of an Experimental, Retrospective Outcome-Based Agreement for a Breast Cancer Treatment in Wales, 2018-2020

    Dec 1, 2022, 00:00

  • CO88 The Impact of COVID-19 Pandemic on Health-Related Quality of Life Outcomes: Evidence From a Longitudinal Study on Children With Rare Disorders

    Dec 1, 2022, 00:00

  • EE625 Economic and Clinical Burden of Worsening Heart Failure Patients With Reduced Ejection Fraction: French National Healthcare Database Analysis (SNDS)

    Dec 1, 2022, 00:00

  • EE519 Cost Effectiveness Analysis of Avacopan in Antineutrophil Cytoplasm Antibody-Associated Vasculitis - A Canadian Perspective

    Dec 1, 2022, 00:00

  • EE487 Quantifying the Economic Burden of Obstructive Hypertrophic Cardiomyopathy (HCM) in the UK

    Dec 1, 2022, 00:00

  • HTA24 Real-World Data as External Controls for Single-Arm Trials: Role in Regulatory and Health Technology Assessments

    Dec 1, 2022, 00:00

  • CO111 Evaluating Mediator Factors Affecting Breast Cancer Screening in American Women: An Application of the Andersen's Behavioral Model to 2011 to 2015 MEPS Panel Data

    Dec 1, 2022, 00:00

  • EE46 High Doses of Treprostinil Could Entail Lower Hospitalization Costs in Patients With Pulmonary Arterial Hypertension in Nine European Countries

    Dec 1, 2022, 00:00

  • P48 Evaluating the Clinical, Economic, and Societal Value of Rapid Diagnostic Testing in Emerging Markets: A Systematic Literature Review Assessing Infectious Diseases

    Dec 1, 2022, 00:00

  • EPH58 A Theoretical Estimation of the Future Prevalence of Osteoporosis in Patients Undergoing Spine Fusion Surgery in Japan by 2050

    Dec 1, 2022, 00:00

  • HSD102 Physicians’ Experience and Perceptions of Tetrabenazine for the Treatment of Huntington Disease-Related Chorea

    Dec 1, 2022, 00:00

  • EE245 Impact of Modelling the Inclusion of Productivity Losses in Economic Analyses of Vaccines for Clostridioides Difficile Infections and Respiratory Syncytial Virus

    Dec 1, 2022, 00:00

  • CO115 Impact of Patient Blood Management (PBM) on the Reduction of Transfusion Requirements in Patients Undergoing Major Planned Orthopedic Surgery in Italy

    Dec 1, 2022, 00:00

  • EE496 Triple Negative Breast Cancer-Related Mortality in Central and Eastern Europe: Years of Life Lost and Productivity Costs

    Dec 1, 2022, 00:00

  • RWD69 Healthcare Resource Use by European Patients Enrolled in RA-BE-REAL: 12 Month Data From a Multinational, Prospective, Observational Study of Patients With Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • MT20 Improving Perioperative Efficiency in the Management of Surgical Sets for Trauma Surgeries: The 4S Approach

    Dec 1, 2022, 00:00

  • HTA122 Health-Related Quality of Life in the German Early Benefit Assessment

    Dec 1, 2022, 00:00

  • RWD33 Analysis of COVID-19 Vaccine-Related Adverse Events in Adults, Geriatrics and Pediatrics – A Retrospective Study

    Dec 1, 2022, 00:00

  • MSR67 Automation of Abstract Screening: A Case Study of Multiple Systematic Literature Reviews

    Dec 1, 2022, 00:00

  • EE461 Cost-Effectiveness of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence With Tumor Cell Pd-L1 Expression ≥ 1% in Denmark

    Dec 1, 2022, 00:00

  • OP8 Developing Sustainable Partnerships Between Pharmaceutical Industry and Public and Non-Profit Organisations: Report of a Roundtable Discussion

    Dec 1, 2022, 00:00

  • EE315 Cost-Effectiveness Analysis of Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes in China

    Dec 1, 2022, 00:00

  • EE319 Building a Cost-Effectiveness Model for Hypertrophic Cardiomyopathy: A Literature Review

    Dec 1, 2022, 00:00

  • RWD45 Real-World Data to Support Surrogate Endpoint Evaluation for Health Technology Assessment

    Dec 1, 2022, 00:00

  • PCR286 Literature Review of Patient-Reported Outcome Measures in Multiple Myeloma: Trends and Considerations for Future Clinical Trials

    Dec 1, 2022, 00:00

  • HTA74 Novel Approach to Decision Making for Orphan Drugs

    Dec 1, 2022, 00:00

  • SA29 Adopting Clinical Trial Best practices of Hybrid Decentralized and Risk Based Quality Management (RBQM), to Help Optimize Prospective Observational (Real-World Evidence) Studies in Compliance, Cost and Time Criteria

    Dec 1, 2022, 00:00

  • MSR132 Integrating Relative Survival Framework for Survival Extrapolation in Multi-State Models—An Application to Predicting Quality-Adjusted Life Years for Chronic Myeloid Leukemia Patients

    Dec 1, 2022, 00:00

  • HTA208 Health Technology Assessment Impact on the Health Care System in Challenging Times in Ukraine

    Dec 1, 2022, 00:00

  • EE542 Health Experiences, Well-Being and Preferences in Health Priority Settings

    Dec 1, 2022, 00:00

  • EE556 Anti-VEGF Cost Calculator in Wet Age-Related Macular Degeneration and Diabetic Macular Edema in Portugal

    Dec 1, 2022, 00:00

  • MSR110 A Comparison of Stan Versus WinBUGS Software for Conducting Bayesian Hazard Ratio-Based Network Meta-Analysis

    Dec 1, 2022, 00:00

  • RWD57 Epidemiological Study of the Burden of COVID-19 on Depression in Men (DIM) in Pre- and During COVID-19 Pandemic Using Real-World Data

    Dec 1, 2022, 00:00

  • MT3 Comparison of Funding and Reimbursement Routes for Medical Devices in France, Germany, and Spain

    Dec 1, 2022, 00:00

  • EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population

    Dec 1, 2022, 00:00

  • HSD106 Analysis of Diagnostic and Medical Delay Data Among Lung Cancer Patients in 2019 and 2020

    Dec 1, 2022, 00:00

  • MT1 FLT3 Inhibitors for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia: Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EE36 Impact of Home Hospitalization on the Cost of Care for 1ST Line Treatment of Locally Advanced or Metastatic HER2+ Breast Cancer

    Dec 1, 2022, 00:00

  • PCR62 The Australian Paediatric Multi-Instrument Comparison (P-MIC) Study: Data Quality, Feasibility, Acceptability, and Construct Validity of the EQ-5D-Y-3L, EQ-5D-Y5L, CHU9D, PedsQL, HUI, PROMIS-25 and AQoL-6D

    Dec 1, 2022, 00:00

  • EE179 Cost-Effectiveness of Robot-Assisted Total Hysterectomy for Benign Pathologies Compared to Laparoscopic and Open Surgery: A Retrospective Study

    Dec 1, 2022, 00:00

  • EE6 Economic Burden of Severe Asthma in Adults and Children Treated With Omalizumab From 2012 to 2019

    Dec 1, 2022, 00:00

  • RWD52 Relevant Real-World Evidence Landscaping and Data Source Assessment for Vitiligo Patient Research in Europe

    Dec 1, 2022, 00:00

  • PCR51 Reassessing the Acceptability of Risk of Death Associated With Gene Therapy for Duchenne Muscular Dystrophy: A Qualitative Study to Inform Updating a Quantitative Instrument

    Dec 1, 2022, 00:00

  • RWD65 Burden of Developmental Disabilities and Ethnic Differences in Utilization of Non-Pharmacotherapies Among Children in the US

    Dec 1, 2022, 00:00

  • EE675 Cost-Utility Analysis of Metabolic Surgery Compared With Best Medical Care for the Treatment of Comorbid Type 2 Diabetes and Obesity

    Dec 1, 2022, 00:00

  • PCR243 Facilitating and Accelerating Patient-Reported Outcomes (PRO) Selection to Use for Clinical Research and Rare Diseases (RD) - A European Rare Disease Research Coordination and Support Action (ERICA) Project

    Dec 1, 2022, 00:00

  • PCR202 The Nature of Quality Appraisal in Systematic Literature Reviews of Health State Utility Values (HSUVS): A Rapid Evidence Review

    Dec 1, 2022, 00:00

  • EPH27 Examining the Risk Behaviour of Young People

    Dec 1, 2022, 00:00

  • HPR53 Changes to Early Access Scheme in Fran Early Learnings for Orphan Drugs

    Dec 1, 2022, 00:00

  • EE25 Burden of Asthma According to GINA Treatment Steps in the French Constances Cohort

    Dec 1, 2022, 00:00

  • EE520 Cost of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) in Spain: A Delphi Approach

    Dec 1, 2022, 00:00

  • EE257 Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK

    Dec 1, 2022, 00:00

  • HTA32 Does a Major Added Benefit From the G-Ba Correspond to Positive Outcomes Across Major Markets? An Analysis Based on the Prismaccess Database

    Dec 1, 2022, 00:00
  • «
  • 21
  • 22 (current)
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • »